Digital Twins for Precision Medicine and Drug Discovery

Precision medicine keeps promising individualized care and keeps delivering population averages. The gap is structural: single-layer omics analysis cannot capture what a biological system does when its parts interact. Digital Twins (DTs) close that gap, not with more data but with dynamic, patient-specific models that fuse multi-omics, clinical records, and longitudinal monitoring into something that runs forward in time. AI drives the simulation; network biology gives it structure. The result predicts disease trajectories and therapeutic response, rather than merely fitting them.

This review follows the full DT lifecycle, from data ingestion and FAIRification through machine learning personalization to clinical deployment. We propose a five-point operational definition that separates genuine DTs from relabeled statistical models, resting on one requirement: a bidirectional virtual-physical loop, not a static prediction. We also examine the gut microbiome, still underserved despite its complexity, and show how ecological frameworks map host-microbe dynamics for precision nutrition, IBD management, and cancer immunotherapy.

Case studies in oncology and neurodegeneration ground the argument, but the bottlenecks matter more: the drug discovery “Attrition Paradox,” misaligned multi-modal data, and uncertainty quantification most pipelines skip. Ethical exposure runs alongside these gaps. Privacy law (GDPR/HIPAA) and algorithmic bias are not peripheral; left unaddressed, they widen disparities rather than close them. We close with stakeholder-specific recommendations, for researchers, industry, funders, regulators, aimed at Digital Twin ecosystems that are safe and equitable by design, not by afterthought.